On Monday (NASDAQ:MNDY), H.C. Wainwright showed confidence in Cadrenal Therapeutics (NASDAQ: CVKD), raising its price target to $32.00 from the previous $3.00, while maintaining a Buy rating. The firm's decision followed the announcement of Cadrenal's financial results for the third quarter of 2024, which were revealed on November 7.
Cadrenal reported an earnings per share (EPS) of ($2.18), surpassing H.C. Wainwright's estimate of ($2.38) but falling short of the consensus estimate of ($1.93). At the end of the quarter, Cadrenal's financial position was strengthened by $11.3 million, bolstered by the $9.8 million raised in October and the exercise of warrants in November. Despite this, the analyst noted that additional funding would be necessary for the company as it prepares to initiate Phase 3 trials.
The company's upcoming trials will evaluate tecarfarin in patients with left ventricular assist devices (LVADs) and those with end-stage kidney disease (ESKD) and atrial fibrillation (AFib). Cadrenal is collaborating with Abbott, a leading manufacturer of the HeartMate 3 LVAD, the only LVAD currently available in the U.S. Cadrenal is actively developing an LVAD study protocol to advance into Phase 3 trials to evaluate tecarfarin versus warfarin in LVAD patients.
As 2025 nears, Cadrenal is working closely with its contract development and manufacturing organization (CDMO) to finalize preparations for a steady supply of tecarfarin and clinical trial materials for the upcoming Phase 3 trial. The analyst reiterated a Buy rating for Cadrenal and adjusted the price target to reflect the recent 1-for-15 reverse stock split that took place in August.
In other recent news, Cadrenal Therapeutics secured around $5.1 million through the sale of 391,243 shares of common stock. The funds raised are set to boost the company's working capital, notably for the development of tecarfarin and preparation for a pivotal Phase 3 trial. In addition, Cadrenal regained compliance with Nasdaq's minimum bid price requirement, a vital step for the company's continued access to capital markets. The company also implemented a 1-for-15 reverse stock split and made significant amendments to its 2022 Successor Equity Incentive Plan.
Cadrenal is preparing for a critical FDA meeting regarding the clinical trial of tecarfarin, a potential anticoagulant for patients with Left Ventricular Assist Devices. The outcome of this meeting will play a significant role in determining tecarfarin's future development and potential market entry.
Finally, Cadrenal's stockholders approved the appointment of WithumSmith+Brown, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2024. In board-related developments, John Murphy and Robert Lisicki were elected as Class II directors, set to serve until the 2027 Annual Meeting of Stockholders.
InvestingPro Insights
Recent InvestingPro data provides additional context to Cadrenal Therapeutics' (NASDAQ: CVKD) financial situation and market performance. The company's market capitalization stands at $26.55 million, reflecting its current valuation in the market. Despite the positive outlook from H.C. Wainwright, InvestingPro Tips highlight that Cadrenal is "quickly burning through cash" and is "not profitable over the last twelve months," which aligns with the analyst's note about the need for additional funding as the company prepares for Phase 3 trials.
On a positive note, Cadrenal has shown strong market performance recently, with InvestingPro data indicating a 31.41% price return over the last month and an impressive 175.1% return over the last three months. This upward trend supports the increased investor interest following the company's Q3 results and future trial plans.
InvestingPro Tips also reveal that Cadrenal "holds more cash than debt on its balance sheet" and "liquid assets exceed short term obligations," which could provide some financial flexibility as the company moves forward with its clinical trials. However, it's worth noting that analysts "do not anticipate the company will be profitable this year," underscoring the importance of the upcoming Phase 3 trials for Cadrenal's long-term prospects.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for Cadrenal Therapeutics, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.